This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07145151 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 156 participants |
| Design | Interventional, Randomized, Parallel, Masking: Triple |
| Conditions | Metabolic Dysfunction-associated Steatohepatitis (MASH) |
| Interventions | UBT251; Placebo |
| Start | Sep 30, 2025 |
| Primary completion | Jun 4, 2027 |
| Study completion | Aug 31, 2027 |
| Results posted | Not yet |
| Registry last updated | Nov 20, 2025 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose，6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology | Baseline, Week 48 |
25 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP) (Phase 3 NCT07767942)
- UNIGUIDE-1: UBT251 Phase 3 in Type 2 Diabetes on Diet and Exercise Alone (Phase 3 NCT07659574)
- UNIGUIDE-2: UBT251 Phase 3 Against Semaglutide in Type 2 Diabetes (Phase 3 NCT07653477)
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Dose-Finding Study in Type 2 Diabetes (Novo Nordisk Phase 2) (Phase 2 NCT07668388)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
